CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study

In VELIA trial, veliparib combined with carboplatin-paclitaxel, followed by maintenance (veliparib-throughout) was associated with improved progression-free survival (PFS) compared with carboplatin-paclitaxel alone in patients with high-grade ovarian carcinomas. We explored the prognostic value of t...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Benoit, Sehgal, Vasudha, Hosmane, Balakrishna, Huang, Xin, Ansell, Peter J., Dinh, Minh H., Bell-McGuinn, Katherine, Luo, Xizhi, Fleming, Gini F., Friedlander, Michael, Bookman, Michael A., Moore, Kathleen N., Steffensen, Karina D., Coleman, Robert L., Swisher, Elizabeth M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788978/
https://www.ncbi.nlm.nih.gov/pubmed/35867965
http://dx.doi.org/10.1200/JCO.22.00430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788978/
https://www.ncbi.nlm.nih.gov/pubmed/35867965
http://dx.doi.org/10.1200/JCO.22.00430

Ejemplares similares